IntelGenx to Report Fourth Quarter and Full-Year 2020 Financial Results on March 25, 2021 – Conference Call to Follow
IntelGenx Technologies Corp. (TSX-V:IGX, OTCQB:IGXT) will release its fourth quarter and full-year 2020 financial results on March 25, 2021, after market close. The conference call, hosted by CEO Dr. Horst G. Zerbe and CFO Andre Godin, is scheduled for 4:30 PM ET. The call will provide insights into the company’s financial performance and future outlook. IntelGenx is a leader in drug delivery, focusing on pharmaceutical films to meet unmet medical needs, with advanced technologies like VersaFilm® and DisinteQ™.
- IntelGenx specializes in innovative drug delivery technologies, which may drive future growth.
- Upcoming conference call to discuss financial results could provide insights into the company's performance.
- None.
SAINT LAURENT, Quebec, March 18, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that it will release its fourth quarter and full-year 2020 financial results after market close on Thursday, March 25, 2021.
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, Chief Executive Officer, and Mr. Andre Godin, President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:
| Fourth Quarter and Full-Year 2020 Results Conference Call Details: | |
| Date: | Thursday, March 25, 2021 |
| Time: | 4:30 p.m. ET |
| Live Call: | 1- 877-876-9174 (Canada and the United States) |
| 1- 785-424-1669 (International) | |
The call will also be broadcast live and archived on the Company's website at www.intelgenx.com under "Webcasts" in the Investors section.
About IntelGenx
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
IntelGenx’s superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.
IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking statements. Each of the TSX Venture Exchange and OTCQB has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
For IntelGenx:
Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
stephen@intelgenx.com
Or
Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com
FAQ
When will IntelGenx release its Q4 and full-year 2020 financial results?
What time is the IntelGenx conference call regarding its financial results?
Who will be hosting the IntelGenx conference call?
What is IntelGenx's focus in the pharmaceutical sector?
